Issue link: https://www.e-digitaleditions.com/i/1469783
The industry organizations page of the Inhalation website provides descriptions and contact information for cross-industry organizations and groups that present educational conferences and workshops. 34 June 2022 Inhalation a life-threatening event, based on patients' SABA overuse. In addition, the results suggest dig- ital inhalers may help healthcare professionals identify and address SABA reliever overuse and help inform clinical decision-making based on individual insights from objective patient SABA reliever usage data downloaded directly from their ProAir Digihaler. Insmed study shows hospitalizations significantly reduced following Arikayce initiation BRIDGEWATER, NEW JER- SEY—Insmed announced they presented new data about three drugs during the American o- racic Society (ATS) 2022 Inter- national Conference, including Arikayce, a novel, inhaled formu- lation of amikacin, an established antibiotic. Administered once daily using the Lamira ® Nebu- lizer System manufactured by PARI Pharma GmbH (PARI), it uses Insmed's proprietary Pulmo- vance ® liposomal technology to deliver amikacin directly to the lungs. Arikayce is approved in the United States, Europe and Japan. In an analysis of 331 patients, researchers found both all-cause and respiratory disease-related hospitalizations were significantly reduced in the 12 months follow- ing Arikayce initiation. CALENDAR Please visit the industry organi- zations page of the Inhalation website to find descriptions and contact information for cross- industry organizations and groups that present educational confer- ences and workshops. https://www.inhalationmag.com/ industry-organizations potential for the Teva ProAir ® Digihaler ® (albuterol sulfate) to help inform treatment discussions and decisions. e findings were presented at the American o- racic Society (ATS) 2022 Annual Meeting. Data on SABA usage among 359 patients downloaded from ProAir Digihaler devices were evaluated. e company news release noted the findings are the first application of evidence-based clinical statements from an inde- pendent US expert consensus that identify risk of asthma exac- erbation, including potential for Teva findings highlight potential of ProAir ® Digihaler ® TEL AVIV, ISRAEL and PAR- SIPPANY, NEW JERSEY—Teva Pharmaceuticals announced its new study findings, based on newly established clinical thresh- olds on short-acting beta agonist (SABA) use, that highlight real- world SABA usage among patients with asthma in the US and the Trusted, Reliable Contract Development & Manufacturing renpharm.com R&D Services – Formulation – Scale-up – Stability – 2-100 mL vials – 2-100 mL vials Injectables – Multi-Dose – Unit Dose – Bi-Dose Multi-Dose – Unit Dose – Bi-Dose Nasal Renaissance develops and manufactures high-quality pharmaceuticals to fulfill your patients' needs. INDUSTRY NEWS continued from page 8